Signe Regner Michaelsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1939274/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	16.8	376
2	Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer, 2013, 13, 402.	2.6	68
3	Targeting glioma stemâ€like cell survival and chemoresistance through inhibition of lysineâ€specific histone demethylase <scp>KDM</scp> 2B. Molecular Oncology, 2018, 12, 406-420.	4.6	56
4	VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro-Oncology, 2018, 20, 1462-1474.	1.2	56
5	Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Cellular Oncology (Dordrecht), 2017, 40, 21-32.	4.4	52
6	Assessment of Quantitative and Allelic <i>MGMT</i> Methylation Patterns as a Prognostic Marker in Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2016, 75, 246-255.	1.7	33
7	The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Management and Research, 2014, 6, 373.	1.9	32
8	Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma. Frontiers in Oncology, 2019, 9, 1425.	2.8	30
9	Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. Journal of Nuclear Medicine, 2016, 57, 272-278.	5.0	27
10	Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. Oncotarget, 2019, 10, 4397-4406.	1.8	27
11	Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors. Neuro-Oncology, 2022, 24, 1074-1087.	1.2	27
12	Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Molecular Oncology, 2016, 10, 1160-1168.	4.6	22
13	Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. Journal of Neuro-Oncology, 2018, 137, 533-542.	2.9	19
14	DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas. International Journal of Molecular Sciences, 2018, 19, 679.	4.1	19
15	The Use of Longitudinal 18F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts. PLoS ONE, 2014, 9, e100009.	2.5	19
16	Single agent―and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells. Journal of Gene Medicine, 2012, 14, 445-458.	2.8	18
17	Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer, 2017, 17, 278.	2.6	16
18	Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study. Molecular Oncology, 2020, 14, 2727-2743.	4.6	14

#	Article	IF	CITATIONS
19	Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. Acta OncolÃ ³ gica, 2016, 55, 418-422.	1.8	11
20	Comparison of 18F-FET and 18F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma. Nuclear Medicine and Biology, 2016, 43, 198-205.	0.6	10
21	A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution. Frontiers in Oncology, 2021, 11, 597587.	2.8	10
22	18F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PIGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma. PLoS ONE, 2015, 10, e0115315.	2.5	8
23	Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro. Cancer Cell International, 2016, 16, 34.	4.1	8
24	Extracranial metastases in glioblastoma—Two case stories. Clinical Case Reports (discontinued), 2019, 7, 289-294.	0.5	6
25	Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Cancer Investigation, 2018, 36, 165-174.	1.3	5
26	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2015, 27, 149.	16.8	3
27	Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Molecular Oncology, 2020, 14, 964-973.	4.6	2
28	VEGF-C as a putative therapeutic target in cancer. Oncotarget, 2019, 10, 3988-3990.	1.8	2
29	Abstract 1369: Inhibition of Notch- and EGFR signaling reduces cell viability and angiogenesis in glioblastoma multiforme. , 2015, , .		1
30	MTR-18PREDICTIVE BIOMARKERS OF BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2015, 17, v128.2-v128.	1.2	0
31	ANGI-15COMBINED TARGETING OF NOTCH AND EGFR DISPLAY ADDITIVE INHIBITORY EFFECTS ON ANGIOGENESIS AND SURVIVAL IN GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v44.2-v44.	1.2	0
32	DRES-01. ROLE OF HISTONE LYSINE DEMETHYLASE KDM2B IN GLIOBLASTOMA TUMOR CELL MAINTENANCE AND CHEMORESISTANCE. Neuro-Oncology, 2017, 19, vi63-vi64.	1.2	0
33	PATH-21. ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2018, 20, vi162-vi163.	1.2	0
34	EPID-13. IDENTIFICATION OF PROGNOSTIC MARKERS IN A COHORT OF CONSECUTIVE NON-SELECTED GLIOBLASTOMA PATIENTS RECEIVING STANDARD THERAPY. Neuro-Oncology, 2019, 21, vi77-vi77.	1.2	0
35	PATH-28. ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2019, 21, vi149-vi149.	1.2	0
36	RARE-21. CLINICAL CHARACTERISTICS OF GLIOSARCOMA AND OUTCOME FROM STANDARDIZED TREATMENT RELATIVE TO CONVENTIONAL GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi225-vi226.	1.2	0

#	Article	IF	CITATIONS
37	Abstract 4306: A prognostic model for clinical response to bevacizumab in recurrent glioblastoma multiforme. , 2015, , .		0
38	Angiotensinogen gene silencing to predict bevacizumab response in recurrent glioblastoma patients Journal of Clinical Oncology, 2018, 36, 2027-2027.	1.6	0
39	Development of a prognostic model for glioblastoma patients treated with standard therapy: A prospective study from a single institution Journal of Clinical Oncology, 2018, 36, e14086-e14086.	1.6	0